OligoG is a dry powder drug that has been shown to decrease the thickness of mucus in the lungs and may help individuals with cystic fibrosis clear mucus easier. OligoG may also help improve the effectiveness of some antibiotics. It is administered using a dry powder inhaler and also developed as a liquid for use with a nebulizer.

Status

Two phase 2b trials are now closed and undergoing analysis. A further phase 2b trial in Europe is planned for 2018.

Sponsor

This program is sponsored by AlgiPharma and partially funded by the Cystic Fibrosis Foundation.